JIP
PRTK

Jaffetilchin Investment Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Jaffetilchin Investment Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,675
Closed -$62K – 392
2021
Q3 		$62K Sell
12,675
-12,675
-50% -$69.8K 0.01% 358
2021
Q2 		$165K Buy
25,350
+12,675
+100% +$102K 0.01% 359
2021
Q1 		$89K Hold
12,675
– – 0.01% 355
2020
Q4 		$79K Buy
+12,675
New +$74.6K 0.01% 267

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jaffetilchin Investment Partners's PRTK Position: Q4 2021 in Review

Jaffetilchin Investment Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2021, closing a stake of 12,675 shares — an estimated $62K sold.

Jaffetilchin Investment Partners first reported a position in PRTK in Q4 2020 and held it in 4 quarters. The position peaked at $165K in Q2 2021. 103 funds tracked by Wall St. Rank hold PRTK as of Q4 2021.

  • Jaffetilchin Investment Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 12,675 Paratek Pharmaceuticals, Inc. shares in Q4 2021, an estimated $62K.
  • Jaffetilchin Investment Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 4 quarters.
  • Jaffetilchin Investment Partners's Paratek Pharmaceuticals, Inc. position peaked at $165K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2021.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2021, filed 17 Feb 2022.